Genovis
18.92 SEK
1,631 following
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Genovis
P/E
Median 2019-2025
EV/S
Median 2019-2021
EV/EBIT
Median 2019-2021
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 25.00 | 31.50 | 73.00 | 45.95 | 52.00 | 24.70 | 21.25 |
| Shares | 63.1 | 65.0 | 65.5 | 65.5 | 65.5 | 169.4 | 66.1 |
| Market cap | 1,577.5 | 2,046.4 | 4,778.9 | 3,008.1 | 3,404.2 | 4,185.2 | 1,403.8 |
| Enterprise value | 1,562.5 | 2,002.2 | 4,697.6 | - | - | - | - |
| EV/S | 25.8 | 32.8 | 50.5 | - | - | - | - |
| EV/EBITDA | 115.2 | 233.6 | 155.0 | - | - | - | - |
| EV/EBIT | 155.2 | 637.7 | 191.4 | - | - | - | - |
| P/E | 165.2 | 317.5 | 192.9 | 241.8 | 55.3 | 49.4 | 59.0 |
| P/B | 44.29 | 23.48 | 41.92 | 23.94 | 17.84 | 18.36 | 5.17 |
| P/S | 26.1 | 33.5 | 51.4 | 29.4 | 21.5 | 32.1 | 10.9 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 72.6 % | 81.7 % | 80.4 % | 83.5 % | 66.1 % | 69.6 % | 71.8 % |
| Gearing ratio | - | - | - | - | - | - | 26.9 % |